Clinical trials: Lenvatinib Treatment
Liver Cancer, Sarcopenia
Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.
- Trial name
- NCT05443230
- Testing
- gait speed; ct scan; grip strength and chair stand test
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Advanced Primary Liver Cancer
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
This is an open-label, nonrandomized investigator-initiated clinical trial to evaluate the safety, tolerability, and efficacy of IBR900 cell injection in combination with Lenvatinib or bevacizumab in subjects with advanced…
- Trial name
- NCT05411757
- Testing
- IBR900 combined with Lenvatinib, IBR900 combined with Bevacizumab
- Volunteers
- 12 people
- Sponsor
- Shandong Public Health Clinical Center
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT03008369
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma…
- Trial name
- NCT03433703
- Testing
- Lenvatinib
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Cholangiocarcinoma Non-resectable
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE)…
- Trial name
- CCGLC-009 (NCT06194695)
- Testing
- drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ze-yang Ding, MD
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Hepatocellular Carcinoma
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
This study is a single-center, single-arm, open-label prospective clinical trial. By recording the disease-free progression (PFS), overall survival (OS) and tumor treatment response of the included patients, it is planned to…
- Trial name
- NCT04909866
- Testing
- TACE+Lenvatininb+Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HCC - Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
- Trial name
- Neo-LENTIS (NCT07475026)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Biliary Tract Cancer
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers…
- Trial name
- NCT04211168
- Testing
- Toripalimab plus Lenvatinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking Union Medical College Hospital
Clear Cell Renal Cell Carcinoma
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
This is a phase II, open-label, multicenter, single-arm study evaluating the efficacy and safety of cadonilimab (AK104) in combination with lenvatinib in patients with unresectable advanced or metastatic clear cell renal cell…
- Trial name
- NCT06035224
- Testing
- AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
- Where
- China
- Volunteers
- 28 people
- Sponsor
- RenJi Hospital
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma.
- Trial name
- NCT05147558
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
- Trial name
- NCT05620498
- Testing
- tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma, Biliary Tract Cancer
Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
This is a single center, nonrandom, open-label study aiming to evluate the efficacy and safety of lenvatinib for patients with pretreated advanced biliary tract cancer.
- Conditions
- Cholangiocarcinoma, Biliary Tract Cancer, Targeted Therapy
- Trial name
- LENABC (NCT04656249)
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer, Tumor
MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer
This study will evaluate whether adding MRG003 to an ongoing treatment regimen can produce confirmed tumor shrinkage in patients with EGFR-positive advanced thyroid cancer whose cancer initially benefited from that regimen and…
- Conditions
- Thyroid Cancer, Tumor, Advanced Thyroid Carcinoma
- Trial name
- NCT07874321
- Testing
- Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma (HCC), Artificial Intelligent
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence…
- Conditions
- Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
- Trial name
- NCT07417800
- Testing
- AI adjuvant therapy
- Where
- China
- Volunteers
- 11,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable).
- Conditions
- Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm
- Trial name
- NCT03950609
- Testing
- Everolimus, Lenvatinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma
- Trial name
- NCT05621499
- Testing
- HAIC, Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT05312216
- Testing
- Durvalumab plus Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang University
Small-cell Lung Cancer
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with…
- Trial name
- NCT04951947
- Testing
- JS201 combine with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital